Here, we present effectiveness results for patients receiving vildagliptin (vildagliptin cohort) or another OAD (comparator cohort)
add-on to monotherapy in Bulgaria.
Methods:
The eligible diabetes patients inadequately controlled with current monotherapy were assigned to add-on treatment, which was chosen by the physician based on patient's need. Effectiveness was assessed by glycated hemoglobin (HbA1c) drop and by means of a composite endpoint assessing the proportion of patients responding to treatment (HbA1c \7%) without proven hypoglycemic event and significant weight gain ([5%) after 12 months of treatment.
Results: In total, 754 patients were enrolled in Bulgaria, 384 in the vildagliptin cohort and 369
in the comparator cohort. Mean HbA1c change from baseline was significantly higher with vildagliptin compared to the comparator (-1.35% in the vildagliptin cohort and -0.55% in the comparator cohort, P\0.001). In the vildagliptin cohort, a higher proportion of patients reached the composite endpoint (HbA1c \7%, no hypoglycemic events, no weight gain) when compared to the comparator cohort (vildagliptin: 32.3%; comparator: 8.4%; P\0.001).
Overall, vildagliptin was well tolerated with similarly low incidences of total adverse events (3.4% versus 1.9% in the comparator group) and serious adverse events (2.3% versus 1.1% in the comparator group).
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INTRODUCTION
Almost half of patients with type 2 diabetes mellitus (T2DM) do not achieve globally recognized blood glucose targets [1, 2] . It is difficult to understand the reasons for this, considering that during last decades the armamentarium of resources to treat T2DM has significantly increased. The reasons can be sought in two main directions.
The first trend observed is the dramatic increase in global prevalence of this disease according to the International Diabetes Federation. Currently, the prevalence in the age group 20-79 years is 8.3% (382 million people worldwide), but it is expected to rise with 55% to a prevalence of 10.1% (592 million) by 2035 [3] . For Bulgaria, the number of patients with T2DM in 2013 was 427,000 people in the age group 20-79 years (7.6%) according to the same source. It is expected the prevalence of diabetes in Bulgaria will follow the global trends. The enormous financial resources destined to the treatment of diabetic complications are constantly increasing requiring identification of new therapeutic approaches to delay complications in time.
The second trend observed is the medications available for T2DM, until recently, do not completely address all main pathogenic mechanisms of the disease. It is well known that T2DM is a chronic disease that results from a combination of insulin resistance and insulin deficiency caused by beta-cell dysfunction [4] . The progressive nature of the disease requires effective glycemic control to reduce the risk of long-term micro-and macrovascular complications related to dysglycemia [5] . Metformin is the most widely used oral anti-diabetic drug (OAD) and is recommended as first-line therapy for patients with T2DM [5] . However, as glycemic control deteriorates, patients with T2DM usually require more than one antidiabetic agent to achieve glycemic targets [6] [7] [8] . Sulfonylureas (SUs) are one of the most commonly used second-line treatment options of T2DM [5] in clinical practice usually in combination with metformin [9] . SUs are commonly associated with weight gain and hypoglycemia [5, 10] . In patients with T2DM receiving OADs, both weight gain and hypoglycemia are independently associated with lower treatment satisfaction and lower health-related quality of life [11] . These adverse events are a wellrecognized reason for poor adherence to chronic therapy, which finally results in impaired disease control [12] [13] [14] .
The new therapeutic classes such as incretinbased therapies could be a solution for some of the problems faced in treatment of T2DM, such as improvement of glycemic control for longer periods, limitation of glycemic fluctuations, hypoglycemia, and weight gain. Long-term effectiveness and safety trials are ongoing to investigate the potential of their new mode of action to overcome the burden of diabetes, to improve diabetes control and to eliminate longterm complications, with special focus on cardiovascular outcomes [15] .
International guidelines [5, 16] [18] , VADT [19] , that were conducted and provided arguments of highest level for the evidence-based medicine. Despite RCTs high informative value, these studies have often been blamed for lack of generalizability of their findings because of the precisely enrolled subjects, better therapy compliance, medicines variations and strictly regulated dose regimen. After all, this is not the usual population, and it receives a strictly pre-determined treatment, beyond the usual practice. For all these, RCTs do not correspond to the routine practice and therefore a new type of pragmatic trial needs to be conducted in real-life settings, which will not replace RCTs, but will rather provide additional information and will help build a uniform concept of the treatment of diabetes mellitus [18, [20] [21] [22] . The number of these real-life clinical trials is still too small.
As mentioned above, metformin is used as a therapy of choice for the treatment of T2DM, irrespective of patient's body weight, when adequate results cannot be achieved by diet and physical activity alone [5, 16] . The latest clinical recommendations of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) from 2012 [5] , and of the American Association of Clinical Endocrinologists (AACE) from 2013 [16] suggest that the choice of a second agent to be added in case of inadequate efficiency of metformin monotherapy is based on individual judgment. It is important to underline that in these key strategic papers, the incretin-based therapy is constantly gaining positions, with the tendency to become second-line therapy added on the top of metformin.
A recent meta-analysis conducted to assess the efficacy and safety of all available secondline antihyperglycemic therapies in patients with T2DM inadequately controlled by metformin monotherapy revealed that dipeptidyl peptidase-4 (DPP-4) inhibitors are as effective as the other therapeutic classes in improvement of glycemic control, but with modest benefits with respect to weight gain and overall hypoglycemia [23] .
Maintaining good glycemic control is essential for risk reduction of micro-and macrovascular complications associated with diabetes [24] . DPP-4 inhibitors possess a number of pharmacological attributes that would suggest cardiovascular safety. In addition to glucose lowering and weight neutrality, they lower blood pressure, improve postprandial hyperlipidaemia, reduce inflammatory markers, diminish oxidative stress, and improve endothelial function [25] .
However, large-scale clinical trials, including studies from routine clinical practice, are also needed to identify benefits or harms from this therapy in a real-life setting. Such a study is the multinational study entitled effectiveness of diabetes control with vildaGliptin and vildagliptin/mEtformin (EDGE) with protocol number CLAF237A2404 [26] . Cardiovascular disease (CVD) is a major cause of morbidity and mortality for individuals with diabetes and the largest contributor to the direct and indirect costs of diabetes. The common conditions coexisting with type 2 diabetes (e.g., hypertension and dyslipidemia) are clear risk factors for CVD, and diabetes itself confers independent risk [27] . Bulgaria has one of the highest rates of premature death from cardiovascular disease in Europe [28] and despite clear recommendations in current guidelines for the treatment of T2DM 
METHODS

Study Design
The EDGE was a 1-year, multinational, multicenter, post-authorization, prospective, observational study conducted in 45,868 subjects at 2,957 sites in 27 countries, grouped 
Evaluation Criteria in EDGE Study
The primary effectiveness endpoint (PEP) was defined as the proportion of patients having a treatment response (HbA1c reduction from BL to Month 12 endpoint [0.3%) and no tolerability issues [peripheral edema, proven hypoglycemic event, discontinuation due to a gastrointestinal (GI) event, or weight gain C5%) [30] . As described in the primary manuscript regarding EDGE study results [26] , this composite endpoint was chosen on the basis of the balanced decisions that clinicians need to make when choosing a glucose-lowering agent, namely the combination of efficacy [as defined by European Medicines Agency (EMA) and the Food and Drug Administration (FDA)] and most common side effects. For more details, please refer to original article [26] .
Patients who could not be categorized as a success or failure (e.g., due to missing HbA1c or body weight data at 12-month endpoint) were considered non-evaluable. Non-evaluable patient data were considered failures in calculation of the odds ratio (OR) for success. Safety was assessed by AE reporting and measurement of specific laboratory values.
Specific attention was given to hepatic safety due to a requirement for liver function monitoring prior and during treatment with vildagliptin [31] .
All these combined endpoints were defined in agreement with the European Medicines Agency when this study was designed.
Statistical Analysis
This post hoc analysis provides mainly descriptive statistics. Inference is provided for primary and secondary endpoints. For these, the probability of success was analyzed using a binary logistic regression model to calculate
ORs with 95% confidence intervals (CIs). The OR expresses odds in favor of success with vildagliptin or vildagliptin/metformin relative to odds in favor of success with comparator
OADs. All statistical evaluations were performed using SAS software, version 9.3 (SAS Institute Inc., Cary, North Carolina, USA. For more details please refer to the original article [26] .
In this post hoc analysis only the unadjusted OR is provided.
RESULTS
In total 754 patients were enrolled in Bulgaria, 384 in the vildagliptin cohort and 369 in the comparator cohort. One patient in the vildagliptin cohort was excluded due to inadequate source documentation or problems with quality/accuracy of data entry ( Table 1) .
The intention-to-treat (ITT) population, used for baseline demographics and safety analyses, comprised 384 and 369 patients receiving dual therapy with newly prescribed vildagliptin or a non-vildagliptin OAD added to prior monotherapy, respectively. The PP population was a subset of the ITT population used for the analyses of effectiveness endpoints and comprised 384 patients in the vildagliptin, and 369 in the comparator cohort. Table 1 . Additional risk factors are presented in Table 3 . Table 4 reports index therapies in the ITT population by cohort. According to distribution by therapy of patients in both groups the majority of subjects in the reference group were on combination of metformin plus SU (90.8%), the second OAD added was AGI or TZD in 9% of subjects. In the vildagliptin group, majority of patients were on vildagliptin plus metformin (77.6%) combination, the rest of subjects (22.4%) were on vildagliptin plus SU combination.
PEPs and SEPs HbA1c decreased in both cohorts (vildagliptin cohort -1.35%, comparator cohort -0.55%) (see Table 5 ). The drop was significantly greater with vildagliptin compared to comparator (P\0.001) (analysis not pre-specified in protocol (Fig. 2) . The results regarding primary and secondary efficacy and tolerability endpoints are summarized in Table 6 .
Safety
The incidence of AEs was comparable between vildagliptin and comparator cohorts. Table 7 summarizes AEs and SAEs that occurred during study, listed by system organ classes (SOC). In the vildagliptin group, the incidence of AEs was 13 (3. 4%) versus 7 (1.9%) in the comparator group. The SAEs reported were 9 (2.3%) and 4 (1.1%) in the vildagliptin and comparator groups, respectively. Only one hypoglycemic event was reported in the comparator group (use of metformin and SU).
DISCUSSION
The results of the presented sub-analysis of the EDGE study confirmed effectiveness and tolerability of vildagliptin used as a second-line OADs therapy in routine clinical settings in Bulgaria. In the Bulgarian population included in the EDGE study, the mean HbA1c drop from baseline was significantly higher with vildagliptin compared to the comparators (-1.35% in the vildagliptin cohort and -0.55% in the comparator cohort, P\0.001).
In a The enrolled population includes all patients who gave documented informed consent b The intent-to-treat (ITT) population is a subset of the enrolled population and includes all patients who were assigned to new treatment at study start. Sites and/or patients identified with quality and compliance findings, irregular data were excluded from the ITT analysis population c The per protocol (PP) population is a subset of the ITT population. The PP population was used for the analyses of effectiveness endpoints. Patients with the following deviations at baseline assessment were excluded from the per protocol population: patients receiving dipeptidyl peptidase-4 (DPP-4) inhibitors at baseline or within 1 month prior to baseline; patients receiving glucagon-like peptide-1 (GLP-1) mimetics/analogs at baseline or within 1 month prior to baseline; patients receiving insulin at baseline; patients receiving only newly initiated monotherapy or more than two oral antidiabetic medications at baseline; drug-naive patients at baseline (patients not taking any diabetic medication prior to baseline); patients who swapped from one oral anti-diabetic medication or class to another at baseline; patients receiving investigational drug at baseline or 30 days prior to baseline or 5 half-lives prior to baseline; patients receiving more than one oral anti-diabetic medication prior to baseline Maintaining good glycemic control without increasing the risk of CV events is essential requirement for type 2 diabetes therapy nowadays [24, 43] . The presented results regarding overall CV safety are in line with the large meta-analysis showing that vildagliptin was not associated with an increased risk of adjudicated CCV events relative to all comparators in the broad population of type 2 diabetes including patients at increased risk of CCV events [34] . A recently published metaanalysis revealed that DPP-4 inhibitors should be considered to have a neutral effect on CV outcomes [44] . Treatment with DPP-4 inhibitors Data presented as n (%) According to the study design, patient disposition in treatment cohorts was totally based on physician discretion. In the final analysis of the EDGE trial, globally 28, 442 patients in the vildagliptin group, and 15,349 patients in the reference group were included [26] . This ratio of almost 2:1 is quite different than the ratio in the Bulgarian population, which is approximately 1:1 (384 in the vildagliptin group and 369 in the comparator group). The preferred second-line OADs were SUs (90.8% of patients in the comparator cohort were on combined therapy with metformin and SU). According to the choice where to assign their patients we could conclude that Bulgarian physicians have a rather conservative attitude towards the new drugs compared to their colleagues worldwide. The delayed and conservative approach in treatment intensification is an example of physician barriers that must be overcome before the optimal glycemic control can be obtained [51, 52] . These barriers are often referred to ''clinical inertia'' or ''benign neglect'' which describe recognition of the problem but failure to act upon it [50, 51] .
Other barriers linked to poor glycemic control are treatment side effects, complex treatment regimens, needle anxiety, poor patient education, and the absence of an adequate patient care plan [53] .
Timely treatment intensification combined with good treatment adherence is important for reducing the total health care system costs Table 5 Mean unadjusted change in glycosylated hemoglobin (HbA1c %) from baseline to study endpoint (per protocol population)
Mean baseline HbA1c (%)
Mean HbA1c (%) at study endpoint Mean HbA1c (%) reduction from baseline to study endpoint
Comparator cohort (n = 369) 8.2 7.6 -0.55 Fig. 1 Responder rates (per protocol population; (P\0.001); success: treatment response without tolerability findings (HbA1c reduction-0.3%, without any tolerability issues: peripheral edema, confirmed hypoglycemia, interruption due to GI reactions, and significant weight gain [5%); failure: lack of treatment response and/or occurrence of any of the tolerability issues. Patients who could not be categorized as a success or failure (e.g., due to missing HbA1c or body weight data at 12-month endpoint) were considered non-evaluable. Non-evaluable patient data were considered failures in calculation of the odds ratio for success) (%) of Bulgarian patients achieved primary effectiveness endpoint after 12 months of treatment by groups spent in diabetes area [54] . Non-adherence to therapy is a common problem associated with chronic diseases and one of the major barriers to optimum glycemic control in patients with T2DM, leading to poor treatment outcomes and increased utilization of health care
resources [54] . Non-adherence to therapy is often related to adverse effects associated with the therapy [55] . The presented sub-analysis regarding Bulgarian results from EDGE study confirmed that vildagliptin could be used as effective and well tolerated second-line therapy.
A significantly higher proportion of patients treated with vildagliptin achieved the HbA1c reduction of [0.3% without any tolerability issues: peripheral edema, confirmed hypoglycemic events, treatment interruption due to GI reactions and significant weight gain of [5%. This result is important, as it is hypoglycemia, weight gain and other AEs that lead to significant worsening of compliance and therapy adherence [55] .
Furthermore, comparing the results regarding vildagliptin efficacy determined in RCTs [56] and in routine clinical practice we could conclude that the full power of treatment with vildagliptin is retained in real-life conditions in contrast to comparators with special focus on SUs. In the comparator cohort, approximately 90.8% of patients were treated with combination therapy with [57] . Some of the study limitations could be seen in the conduct of the trial-patients were recruited both in specialized centers and by physicians working in routine care which impacted the overall number of investigators and overall results because of poor quality data and missing data which needed to be excluded from the effectiveness analyses. Safety events were likely underreported as the detection and reporting of
AEs were based on the voluntary reporting Gastrointestinal disorders 1 (7. Data are meaning n (%) Adverse events were coded according to MedDRA version 14.0 [58] Primary system organ classes (SOC)s are presented alphabetically A patient with multiple occurrences of an AE under one cohort is counted only once in the AE category A patient with multiple AEs within a primary system organ class is counted only once in the total row for that cohort Switches from vildagliptin/metformin fixed dose to vildagliptin as add-on dual therapy to metformin and vice versa were not counted as treatment change Total also contains patients without initial dual therapy AE adverse event, ITT intent to treat, SAE serious adverse event scheme which is the most widely used method to identify AEs for new drugs in clinical practice.
The present study is a post hoc analysis and shares all the limitations of secondary analysis such as no adjustment of the results for major potential confounders was not done (e.g., age, sex, duration, baseline HbA1c, baseline BMI).
In conclusion, this study demonstrated that in analogy to findings in the worldwide EDGE study [26] , vildagliptin is both efficacious and safe when used as a second oral glucoselowering agent in Bulgarian cohort of type 2 diabetic patients. In real-life clinical practice in Bulgaria, vildagliptin is a valid option to use in combination with metformin or any other oral glucose-lowering drug in patients with T2DM who require combination therapy. Vildagliptin also provides a greater HbA1c drop, less hypoglycemic events and a higher proportion of patients reaching target HbA1c without hypoglycemia and weight gain compared to other OADs add-on as second-line therapy.
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